Geron Corporation (GERN): Price and Financial Metrics


Geron Corporation (GERN): $1.52

0.02 (+1.33%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add GERN to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

GERN POWR Grades


  • Quality is the dimension where GERN ranks best; there it ranks ahead of 47.8% of US stocks.
  • The strongest trend for GERN is in Momentum, which has been heading down over the past 179 days.
  • GERN's current lowest rank is in the Sentiment metric (where it is better than 9.7% of US stocks).

GERN Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for GERN is 0.01 -- better than merely 7.04% of US stocks.
  • GERN's price/sales ratio is 297.47; that's higher than the P/S ratio of 98.82% of US stocks.
  • Revenue growth over the past 12 months for Geron Corp comes in at 450.59%, a number that bests 98.13% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Geron Corp are VTGN, STTK, VBLT, GNCA, and AYLA.
  • GERN's SEC filings can be seen here. And to visit Geron Corp's official web site, go to www.geron.com.

GERN Valuation Summary

  • GERN's price/sales ratio is 1156.5; this is 30334.21% higher than that of the median Healthcare stock.
  • Over the past 243 months, GERN's price/sales ratio has gone up 1098.9.
  • GERN's EV/EBIT ratio has moved up 6.1 over the prior 243 months.

Below are key valuation metrics over time for GERN.

Stock Date P/S P/B P/E EV/EBIT
GERN 2021-08-31 1156.5 2.6 -4.6 -4.5
GERN 2021-08-30 1148.5 2.6 -4.6 -4.5
GERN 2021-08-27 1132.6 2.6 -4.5 -4.4
GERN 2021-08-26 1076.6 2.5 -4.3 -4.2
GERN 2021-08-25 1084.6 2.5 -4.3 -4.2
GERN 2021-08-24 1044.8 2.4 -4.2 -4.1

GERN Growth Metrics

    The 4 year price growth rate now stands at -40.37%.
  • The 4 year cash and equivalents growth rate now stands at 57.35%.
  • Its 4 year net cashflow from operations growth rate is now at -159.57%.
Over the past 70 months, GERN's revenue has gone down $35,190,000.

The table below shows GERN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 1.393 -95.556 -116.112
2021-09-30 0.403 -86.002 -107.882
2021-06-30 0.402 -78.611 -100.836
2021-03-31 0.338 -73.192 -87.086
2020-12-31 0.253 -66.652 -75.617
2020-09-30 0.374 -64.404 -80.9

GERN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • GERN has a Quality Grade of C, ranking ahead of 52.18% of graded US stocks.
  • GERN's asset turnover comes in at 0.002 -- ranking 426th of 682 Pharmaceutical Products stocks.
  • NSTG, NEOG, and CLVS are the stocks whose asset turnover ratios are most correlated with GERN.

The table below shows GERN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.002 1 -0.424
2021-03-31 0.001 1 -0.352
2020-12-31 0.001 1 -0.350
2020-09-30 0.002 1 -0.448
2020-06-30 0.002 1 -0.503
2020-03-31 0.003 1 -0.589

GERN Price Target

For more insight on analysts targets of GERN, see our GERN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $4.20 Average Broker Recommendation 1.38 (Strong Buy)

GERN Stock Price Chart Interactive Chart >

Price chart for GERN

GERN Price/Volume Stats

Current price $1.52 52-week high $1.74
Prev. close $1.50 52-week low $0.99
Day low $1.41 Volume 2,147,500
Day high $1.53 Avg. volume 2,432,032
50-day MA $1.38 Dividend yield N/A
200-day MA $1.32 Market Cap 573.72M

Geron Corporation (GERN) Company Bio


Geron Corporation focuses on the development of telomerase inhibitor, imetelstat, for treating hematologic myeloid malignancies. The company was founded in 1990 and is based in Menlo Park, California.


GERN Latest News Stream


Event/Time News Detail
Loading, please wait...

GERN Latest Social Stream


Loading social stream, please wait...

View Full GERN Social Stream

Latest GERN News From Around the Web

Below are the latest news stories about Geron Corp that investors may wish to consider to help them evaluate GERN as an investment opportunity.

Geron: Just One More Year Of Patience, Then Decision Time

Just when I thought Geron (GERN) could not go down any further, I see it is down 42% since my last coverage in June. That is sad, because in imetelstat Geron has one of the most promising, pioneering cancer technology in the sector, and yet, despite all its promise, the...

Avisol Capital Partners on Seeking Alpha | February 23, 2022

Could The Geron Corporation (NASDAQ:GERN) Ownership Structure Tell Us Something Useful?

Every investor in Geron Corporation ( NASDAQ:GERN ) should be aware of the most powerful shareholder groups. Large...

Yahoo | January 31, 2022

Geron (GERN) Investor Presentation - Slideshow

No summary available.

Seeking Alpha | January 28, 2022

Karyopharm's (KPTI) Eltanexor Gets Orphan Drug Tag for MDS

The FDA bestows an Orphan Drug status to Karyopharm's (KPTI) investigational candidate, eltanexor, for treating myelodysplastic syndromes.

Yahoo | January 26, 2022

Geron to Present at the B. Riley Securities Virtual Oncology Investor Conference

FOSTER CITY, Calif., January 21, 2022--Geron to Present at the B. Riley Securities Virtual Oncology Investor Conference

Yahoo | January 21, 2022

Read More 'GERN' Stories Here

GERN Price Returns

1-mo 10.14%
3-mo 0.00%
6-mo 24.59%
1-year 7.80%
3-year 7.80%
5-year -45.13%
YTD 24.59%
2021 -23.27%
2020 16.91%
2019 36.00%
2018 -44.44%
2017 -13.04%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4971 seconds.